Top Markets
Coin of the day
Psyence Biomedical Ltd. Psyence Biomedical Ltd.

Psyence Biomedical Ltd.

PBM
株式のランク #40930
Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines... Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines formulated from botanical psilocybin. The firm is actively exploring natural psilocybin as a potential therapy for adjustment disorder experienced by patients with an incurable cancer diagnosis undergoing palliative care. Its leading investigational drug, PEX010, a capsule made with naturally sourced psilocybin, is currently in a Phase IIb clinical study. This product is being developed to treat anxiety, depression, and associated conditions such as post-traumatic stress disorder (PTSD), stress, grief, and adjustment disorder, especially in a palliative care context. Psyence Biomedical has partnered with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010, utilizing psilocybin-assisted psychotherapy for adjustment disorder arising from incurable cancer. Additionally, the company holds a strategic alliance with PsyLabs for the manufacturing of Ibogaine. Headquartered in Toronto, Canada, Psyence Biomedical Ltd. functions as a subsidiary of Psyence Group Inc.
株価
$3.20
最終同期: 2026-07-31
時価総額
$60.86K
変化(1日)
-4.76%
変化(1年)
-83.44%
CA
取引 Psyence Biomedical Ltd. (PBM)

カテゴリー

Psyence Biomedical Ltd.(PBM)の株式分割履歴
Psyence Biomedical Ltd.株(シンボル:PBM)は合計で0回の株式分割を実施しました。
最新の株式分割はAug 13, 2026に行われました。
Aug 13, 2026より前に購入されたPBM株は、現在0PBM株に相当します。
株式分割一覧
株式分割 分割比率 累積分割比率
提供された日付のデータは十分ではありません。
類似企業または競合他社の株式分割
企業 株式分割の回数 累積分割比率
1 x2
US
0 -
NL
0 -
CH
0 -
KR
0 -
BE